Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
TUSTIN, Calif., Jan. 02, 2018 -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a company committed to improving patient lives by manufacturing and delivering high quality biologics, today announced that its president and chief executive officer, Roger J. Lias, Ph.D., will deliver a corporate presentation at the 10th Annual Biotech Showcase™, being held January 8-10, 2018 at the Hilton San Francisco Union Square in San Francisco.
Details of this presentation are as follows:
- Biotech Showcase 2018
Time/Date: 3:30 p.m. PT on Monday, January 8, 2018
Location: Hilton San Francisco Union Square
Room: Yosemite – B (Ballroom Level)
About Peregrine Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc. is a company transitioning from an R&D focused business to a pure play contract development and manufacturing organization (CDMO). Peregrine's in-house CDMO services, including cGMP manufacturing and development capabilities, are provided through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com).
Peregrine is pursuing the licensing or sale of its proprietary R&D assets, including its lead immunotherapy candidate, bavituximab, which is currently being evaluated in clinical trials in combination with immune stimulating therapies for the treatment of various cancers. For more information, please visit www.peregrineinc.com.
About Avid Bioservices, Inc.
Avid Bioservices, a wholly owned subsidiary of Peregrine Pharmaceuticals, provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With nearly 25 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid's services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The company also provides a variety of process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization. For more information about Avid, please visit www.avidbio.com.
Contacts: Stephanie Diaz (Investors) Vida Strategic Partners 415-675-7401 [email protected] Tim Brons (Media) Vida Strategic Partners 415-675-7402 [email protected]
